Clinical Trial

Hypofractionated WPPT With HDR Boost

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-09; most recent amendment 2026-02-03.
Status change: Not Yet Recruiting → Recruiting 2024-10-30
Trial Details
NCT Number NCT06591819
Lead Sponsor Abramson Cancer Center at Penn Medicine
Conditions Prostate Cancer
Enrollment 30 participants
Start Date 2025-01-15
Primary Completion 2034-01 (estimated)
Study Completion 2035-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-05